Skip to main content
The University of Arizona Wordmark Line Logo White
Stories & Features Announcements Calendar Leadership Updates Event Planning Room Scheduling Café Bolo Directories IT Support Classroom Support Planning & Facilities
The University of Arizona Health Sciences | Home
Subscribe
Support
home home

Main navigation

  • Overview Senior Leadership Academic Leadership Executive Leadership Annual Report Mission, Values, History Support
  • Overview College of Health Sciences College of Medicine – Phoenix College of Medicine – Tucson College of Nursing Mel and Enid Zuckerman College of Public Health R. Ken Coit College of Pharmacy
  • Research Administration Research Awards and Grants
  • Clinical
  • Overview Community Engagement Alliance Corporate and Community Relations Health and Humanities Rural Health Community Events Student Engagement and Career Advancement
  • Overview Aegis Consortium All of Us Research Program Arizona Area Health Education Centers Arizona Simulation Technology & Education Center Asthma & Airway Disease Research Center Center for Accelerated Biomedical Innovation Center for Advanced Molecular & Immunological Therapies Center for Biomedical Informatics & Biostatistics Center for Disparities in Diabetes, Obesity & Metabolism Center for Innovation in Brain Science Center for Sleep, Circadian & Neuroscience Research Clinical & Translational Sciences Research Center Comprehensive Center for Pain & Addiction Health Sciences SensorLab One Health University of Arizona Cancer Center
  • All News Stories Videos The Healthy Dose Blog News Releases In The Media Media Resources Office of Communications
  1. Home
  2. Node

A Phase 2, multicenter, Open-Label, Long-Term Safety Study of LP352 in Subjects with Developmental and Epileptic Encephalopathy who Completed Study LP352-201 and are Candidates for Continuous Treatmen

Read more about A Phase 2, multicenter, Open-Label, Long-Term Safety Study of LP352 in Subjects with Developmental and Epileptic Encephalopathy who Completed Study LP352-201 and are Candidates for Continuous Treatmen

A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients

Read more about A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients

A Phase 1/2, Safety Lead-in and Dose Expansion, Open-label, Multicenter Trial Investigating the Safety,Tolerability, and Preliminary Activity of Ivosidenib in Combination with Nivolumab and Ipilimumab

Read more about A Phase 1/2, Safety Lead-in and Dose Expansion, Open-label, Multicenter Trial Investigating the Safety,Tolerability, and Preliminary Activity of Ivosidenib in Combination with Nivolumab and Ipilimumab

A Multi-Center, Phase IIA, Randomized, Double-Blind, Prospective, Active Placebo- Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa- Induced Dyskinesia in Subjects

Read more about A Multi-Center, Phase IIA, Randomized, Double-Blind, Prospective, Active Placebo- Controlled Trial of Sub-Anesthetic Intravenous Infusion of Ketamine to Treat Levodopa- Induced Dyskinesia in Subjects

A First-in-human, Multicenter, Open-label, Dose Escalation and Dose Expansion Phase 1 Study in Patients with Advanced Solid Tumors to Evaluate the Safety of Intravenously Administered ALG.APV-527

Read more about A First-in-human, Multicenter, Open-label, Dose Escalation and Dose Expansion Phase 1 Study in Patients with Advanced Solid Tumors to Evaluate the Safety of Intravenously Administered ALG.APV-527

Global Health Equity Scholars Program

Read more about Global Health Equity Scholars Program

eNAMPT-Neutralizing Monoclonal Antibody (ALT-100), as a Novel Treatment of Chorioamnionitis

Read more about eNAMPT-Neutralizing Monoclonal Antibody (ALT-100), as a Novel Treatment of Chorioamnionitis

Validation of Targeting the FAK FAT Domain in Cancer

Read more about Validation of Targeting the FAK FAT Domain in Cancer

Structural Dynamics of Cardiac Myosin-Binding Protein C Regulation

Read more about Structural Dynamics of Cardiac Myosin-Binding Protein C Regulation

Statistical Methods and Software for Multivariate Meta-analysis

Read more about Statistical Methods and Software for Multivariate Meta-analysis

Pagination

  • « First First page
  • ‹ Previous Previous page
  • …
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • …
  • Next › Next page
  • Last » Last page
Subscribe to
The University of Arizona Health Sciences | Home

Health Sciences

  • About
  • Academics
  • Research
  • Centers and Programs
  • Clinical Care
  • Outreach
  • Initiatives

News

  • Stories
  • Healthy Dose Blog
  • News Releases
  • In The Media
  • Media Resources
  • Videos

Internal Resources

  • Stories & Features
  • Announcements
  • Calendar
  • Leadership Updates
  • Honors and Awards
  • Event Planning
  • Room Scheduling
  • Café Bolo
  • El Mirador Project
  • IT Support
  • Classroom Support
  • Planning and Facilities
  • Photo Galleries
  • Directories

Connect

  • Facebook
  • YouTube
  • Instagram
  • LinkedIn
  • X, formerly Twitter

We respectfully acknowledge the University of Arizona is on the land and territories of Indigenous peoples. Today, Arizona is home to 22 federally recognized tribes, with Tucson being home to the O’odham and the Yaqui. The university strives to build sustainable relationships with sovereign Native Nations and Indigenous communities through education offerings, partnerships, and community service.


University Information Security and Privacy

© 2025 The Arizona Board of Regents on behalf of The University of Arizona.